



Published on *British Columbia Drug and Poison Information Centre (BC DPIC)* (<http://www.dpic.org>)

[Home](#) > [Drug Product Listings](#) > Aliskiren and hydrochlorothiazide > Printer-friendly PDF

Aliskiren and hydrochlorothiazide

Trade Name:

Rasilez HCT

Manufacturer/Distributor:

Novartis

www.novartis.ca, 1-800-363-8883

Classification:

Renin inhibitor and diuretic

ATC Class:

C09XA52 Aliskiren and hydrochlorothiazide

Status:

active

Notice of Compliance (yyyy/mm/dd):

2009/09/04

Date Marketed in Canada (yyyy/mm/dd):

2009/09

Presentation:

Tablet: aliskiren 150 mg + hydrochlorothiazide 12.5 mg; DIN 02332728

Tablet: aliskiren 150 mg + hydrochlorothiazide 25 mg; DIN 02332736

Tablet: aliskiren 300 mg + hydrochlorothiazide 12.5 mg; DIN 02332744

Tablet: aliskiren 300 mg + hydrochlorothiazide 25 mg; DIN 02332752

Comments:

For mild to moderate essential hypertension in patients for whom combination therapy is appropriate. Not indicated for initial therapy.

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the [Health Canada Drug Product Database](#)

Status:**Search Terms:**

[A](#) (37) | [B](#) (20) | [C](#) (24) | [D](#) (37) | [E](#) (40) | [F](#) (12) | [G](#) (11) | [H](#) (9) | [I](#) (24) | [K](#) (1) | [L](#) (26)

| M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4)

<u>Generic Name</u>	<u>Common Trade Name(s)</u>	<u>Classification</u>	<u>Date Marketed in Canada (yyyy/mm/dd)</u>
<u>Semaglutide</u>	Ozempic	Incretin mimetic	2018/02/22
<u>Semaglutide</u>	Rybelsus	Incretin mimetic	2020/04/19
<u>Sibutramine</u>	Meridia		2010/10/08
<u>Sildenafil citrate</u>	Revatio IV	cGMP-Specific Phosphodiesterase Type 5 Inhibitor	2010/08/31
<u>Silodosin</u>	Rapaflo	Alpha-1 adrenergic blocker	2012/03/05
<u>Siltuximab</u>	Sylvant	Immunosuppressive agent	2015/01/02
<u>Siponimod</u>	Mayzent	Immunomodulatory agent	2020/04/24
<u>Sitagliptin</u>	Januvia	Hypoglycemic agent	2012/11/20
<u>Sitagliptin and metformin</u>	Janumet	Hypoglycemic agent	2009/09/24
<u>Sitaxsentan</u>	Thelin	Endothelin receptor antagonist	
<u>Sodium zirconium cyclosilicate</u>	Lokelma	Potassium binder	2019/10/17
<u>Sofosbuvir + velpatasvir</u>	Epclusa	Antiviral agent	2016/07/11
<u>Sofosbuvir + velpatasvir + voxilaprevir</u>	Vosevi	Antiviral agent for treatment of chronic hepatitis C infection	2017/09/18
<u>Sonidegib</u>	Odomzo	Antineoplastic agent	2020/06/11
<u>Stiripentol</u>	Diacomit	Antiepileptic	2014/12/21
<u>Sumatriptan + naproxen</u>	Suvexx	Serotonin receptor agonist + NSAID	2020/07/24
<u>Suvorexant</u>	Belsomra	Hypnotic	2019/04/16
<u>Tadalafil</u>	Adcirca	cGMP-specific phosphodiesterase type 5 inhibitor	2009/11/25
<u>Tafamidis</u>	Vyndaqel	Selective stabilizer of transthyretin - cardiac drug	2020/04/07
<u>Tamsulosin + dutasteride</u>	Jalyn	Alpha-1 blocker + 5-Alpha reductase inhibitor	2012/02/03
<u>Tapentadol</u>	Nucynta CR	Opioid analgesic	2011/03/01

<u>Generic Name</u>	<u>Common Trade Name(s)</u>	<u>Classification</u>	<u>Date Marketed in Canada (yyyy/mm/dd)</u>
<u>Tapentadol</u>	Nucynta IR	Opioid analgesic	2012/03
<u>Tedizolid</u>	Sivextro	Oxazolidinone antibiotic	2015/10/08
<u>Telaprevir</u>	Incivek	Antiviral agent	2011/10/06
<u>Telmisartan + amlodipine</u>	Twynsta	Angiotensin II antagonists and calcium channel blockers	2011/08/03
<u>Telotristat ethyl</u>	Xermelo	Tryptophan hydroxylase inhibitor	2018/10/12
<u>Tenapanor</u>	Ibsrela	Sodium/hydrogen exchanger inhibitor	2020/11/23
<u>Tepotinib</u>	Tepmetko	Protein kinase inhibitor (antineoplastic agent)	
<u>Teriflunomide</u>	Aubagio	Immunomodulator agent	2013/11/15
<u>Teriparatide</u>	Osnuvo	Bone formation agent	2020/10/27
<u>Testosterone</u>	Natesto	Androgen	2016/05/06
<u>Tetracaine</u>	Pontocaine (spinal anesthesia)	Local anesthetic	
<u>Thalidomide</u>	Thalomid	Immunomodulatory agent	2010/08/06
<u>Tibolone</u>	Tibella	Hormone replacement therapy	2020/07/29
<u>Ticagrelor</u>	Brilinta	Platelet aggregation inhibitor	2011/06/01
<u>Tiotropium + olodaterol</u>	Inspiolto Respimat	Bronchodilator combination - LAMA plus LABA	2015/05/29

« [first](#) [previous](#) ? [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) **10** [11](#) [12](#) [next](#) ? [last](#) »

We are grateful to all the First Nations who have cared for and nurtured the lands and waters around us for all time, including the xʷmʷkʷyʷm (Musqueam), Skʷwxʷwʷmesh Uʷxwumixw (Squamish Nation), and sʔlʔilwʔtaʔ (Tsleil-Waututh Nation) on whose unceded and ancestral territory our centre is located.

© 2024 BC Drug and Poison Information Centre

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is *not* meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the **full terms and conditions** below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more

detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

Terms and Conditions

Source URL (retrieved on 2025-05-10 21:52): <http://www.dpic.org/druglisting/aliskiren-and-hydrochlorothiazide>